AZD4547

Catalog No.S2801

AZD4547 Chemical Structure

Molecular Weight(MW): 463.57

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Treatment of human CECs with of IL-1β (*, P < 0.01) and FGF2 (+, P < 0.01) resulted in enhanced cell migration as measured in a scratch-induced directional migration assay. Cotreatment with AZD4547 (AZD), an antagonist against FGF receptors 1 to 3, abolished the FGF2-enhanced (++, P < 0.01) but not the IL-1β-enhanced (P > 0.05) migration in human CECs. One-way ANOVA: F(4, 80) = 512, P < 0.00001, n =17 per sample. Tukey's post hoc test, HSD[0.05] = 10.9; HSD[0.01] = 13.1.

    Mol Cell Biol 2014 34(18), 3535-45. AZD4547 purchased from Selleck.

    FCM evaluating lung CD11b+/Gr1+ myeloid cells isolated from 4T1 tumor-bearing mice after 20 days of treatment with AZD4547 or control. Statistical significance was assessed by unpaired t test.

    Cell Physiol Biochem 2014 33(3), 633-45. AZD4547 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.
Features Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
Targets
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
FGFR4 [1]
(Cell-free assay)
0.2 nM 1.8 nM 2.5 nM 24 nM 165 nM
In vitro

Compared to FGFR1-3, AZD4547 displays weaker activity against FGFR4 with IC50 of 165 nM. AZD4547 only inhibits recombinant VEGFR2 (KDR) kinase activity with IC50 of 24 nM, in the in vitro selectivity test against a diverse panel of representative human kinases. AZD4547 at 0.1 μM exhibits no activity against a range of recombinant kinases including ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2, and PI3-kinase. Consistently, the potent selectivity of AZD4547 for FGFR1-3 over FGFR4, IGFR, and KDR is also observed in cellular phosphorylation assays. AZD4547 has potent in vitro antiproliferative activity only against tumor cell lines expressing deregulated FGFRs such as KG1a, Sum52-PE, and KMS11 with IC50 of 18-281 nM, and is inactive against MCF7 as well as more than 100 additional tumor cell lines. AZD4547 treatment potently inhibits FGFR and MAPK phosphorylation in human tumor cell lines in a dose-dependent manner. AZD4547 also potently inhibits the phosphorylation of FRS2 and PLCγ, downstream markers of FGFR signaling. Notably, AZD4547 affects the AKT phosphorylation in the breast cell lines, MCF7 and Sum52-PE but not in KG1a and KMS11 lines. AZD4547 treatment significantly induces apoptosis in Sum52-PE and KMS11 cells, dramatically increases G1 arrest but not apoptosis in KG1a cells, and has no effect on cell cycle distribution or apoptosis in MCF7 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SNU449 NFO3RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\6O|IhcA>? NEPYSoFKSzVyPUCuNFgzKM7:TR?= NF7DbXkzPjN3MUOyNC=>
SK-HEP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvmO|IhcA>? Ml3jTWM2OD1yLkC4OEDPxE1? M1T2dFI3OzVzM{Kw
SNU475 MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HEWFczKGh? M3;6fGlEPTB;NT60JO69VQ>? M1\BSlI3OzVzM{Kw
Hep3B MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[5T|k4OiCq NGPxXYtKSzVyPU[uOFMh|ryP NFzCZ3IzPjN3MUOyNC=>
PLC/PRF5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvNWFlvPzJiaB?= M{LFPWlEPTB;Nj61OUDPxE1? MViyOlM2OTN{MB?=
Hur7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX23NkBp Mo[wTWM2OD15LkK1JO69VQ>? NG\PdIMzPjN3MUOyNC=>
HepG2 M{LifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1njVlczKGh? NFfJRmxKSzVyPUiuO|Mh|ryP M1PadlI3OzVzM{Kw
SNU449 M1iwW2Ntd26xZ3XubYMh[XO|YYm= MX6xJOK2VQ>? MVSyOEBp MUPk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDzbYdvcW[rY3HueIx6 M4nqPFI3OzVzM{Kw
SK-HEP-1 MYnDcI9vd2enbnnjJIF{e2G7 MmmwNUDDvU1? NXrIbG81OjRiaB?= NU\Fco1n\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?= MoL3NlY{PTF|MkC=
SNU449 NHqyNoVHfW6ldHnvckBCe3OjeR?= M1T2RlAuOiEQvF2= M3;CTFQ5KGh? M{[4b4NifXOnczDhJIRm[3KnYYPlJI9nKE[UU{NvwKxCU1RuIHHu[EBGWkticHjvd5Bpd3K7bHH0bY9v NFm4bpEzPjN3MUOyNC=>
SK-HEP-1 NULLPGY6TnWwY4Tpc44hSXO|YYm= MmfiNE0zKM7:TR?= NYDJSlhVPDhiaB?= Mke3Z4F2e2W|IHGg[IVkemWjc3Wgc4YhTlKVMv-8kGFMXCxiYX7kJGVTUyCyaH;zdIhwenmuYYTpc44> NV;0WmVVOjZ|NUGzNlA>
BaF3 FLT3-TEL M3nuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnVSYNIUTVyPUSuOkDDuSByLkW3O{DPxE1? MVmyOlI6PDd2MR?=
BaF3 RET-TEL NWnifXpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjGN5ZIUTVyPUCuN|khyrFiMD6wOFgh|ryP NHnSeJQzPjJ7NEe0NS=>
BaF3 Parental NVvIfnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf5VWhLT0l3MP-5qVExKM7:TR?= MUGyOlI6PDd2MR?=
MOLM14 FLT3/ITD M2DEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P1VGdKPTB;MD60PFQhyrFiMD6xOVch|ryP M4PGVlI3Ojl2N{Sx
MV4-11 FLT3/ITD NH\M[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxS2k2OD1yLkS1PUDDuSByLkC0OkDPxE1? NXT6Z2xTOjZ{OUS3OFE>
TT RET C634W NHnkfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\HTVUxRTJwOTFCtUAxNjlyNDFOwG0> M{fFclI3Ojl2N{Sx
AN3-CA FGFR2 N550K, K310R NUf4Zox3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTHTVUxRTBwMEOxJOKyKDBwMEKzJO69VQ>? NYf3O2JEOjZ{OUS3OFE>
MFE296 FGFR2 N550K M3TXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXXZ3FIUTVyPUCuO|MxKMLzIECuNFU4KM7:TR?= M4X2elI3Ojl2N{Sx
MFE280 FGFR2 S252W M4fBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDHTVUxRTBwMkG4JOKyKDBwMEezJO69VQ>? M3zqZVI3Ojl2N{Sx
Ishikawa FGFF2 over exp. NWDT[WtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;HTVUxRTRwNTFCtUAyNjVzIN88US=> MnrsNlYzQTR5NEG=
HEC1A Normal FGFR2 NHTzcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXDNopIUTVy78olNVAh|ryP MWKyOlI6PDd2MR?=
A549 NXnGbmtCS2WubDD2bYFjcWyrdImgRZN{[Xl? NFPVc2YxNjFxMTFOwG0> MXy0PEBp MkH3[Y5p[W6lZYOgSZJtd3SrbnniJIlv\HWlZXSgeoli[mmuaYT5JIxwe3N? M4n1eVI3ODV|MEKw
SGC-7901 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3lSo0yKG6PLUGwJO69VQ>? M3XkSFczKGh? M1rLSGlEPTBib3[gOU0yOCEQvF2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFuzWWUzPTV5NkmxOS=>
HGC-27 NVfXWox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDvNUBvVS1zMDFOwG0> NV;1SFlTPzJiaB?= MVvJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NGX2UlczPTV5NkmxOS=>
MKN-28 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzENUBvVS1zMDFOwG0> MoXSO|IhcA>? MXzJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NIDWWJozPTV5NkmxOS=>
NCI-N87 M17ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixJI5ONTFyIN88US=> M3nxdlczKGh? NVnlZVFmUUN3MDDv[kA2NTFyIN88UUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NWn4bFFGOjV3N{[5NVU>
KATOIII MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxJI5ONTFyIN88US=> NXPscJYxPzJiaB?= MVrJR|UxKG:oIEGwMVExOCCwTTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MormNlU2PzZ7MUW=
SNU-16 NVzLd2hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxJI5ONTFyIN88US=> MlHpO|IhcA>? NWf1ZlRSUUN3MDDv[kAyOC1zMECgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= Mo\rNlU2PzZ7MUW=
4T1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnYU5BKSzVyPUCuOlTDuTBwMUGg{txO MXSyOFY1Ojh7Mx?=
MDA-MB-468 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL3SIJKSzVyPUSuPeKyOC56NTFOwG0> MVeyOFY1Ojh7Mx?=
HCT116 M2Hrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;1VmlEPTB;MUWuPeKyOS56MjFOwG0> MWCyOFY1Ojh7Mx?=
SW620 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;JR2lEPTExvK6yNEDPxE1? MVmyOFY1Ojh7Mx?=
MDA-MB-231 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHhd24yUUN3MP-8olIxKM7:TR?= MYCyOFY1Ojh7Mx?=
CT26 M2P5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTLfHJjUUN3MP-8olIxKM7:TR?= MXiyOFY1Ojh7Mx?=
SW480 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrQTWM2OO,:nkKwJO69VQ>? NFzhcmUzPDZ2Mki5Ny=>
4T1 MUXBdI9xfG:|aYOgRZN{[Xl? MVqxMlI2NTJyIN88US=> MVyyOEBp NULkRYNjcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> MYqyOFY1Ojh7Mx?=
KG1a MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W4O2lEPTB;MD6wNVgh|ryP M3j3flIzOzZ7OUK4
Sum52-PE M3fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofRTWM2OD1yLkC0NUDPxE1? MUmyNlM3QTl{OB?=
KMS11 M{K3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrVSY5yUUN3ME2wMlI5OSEQvF2= MnrYNlI{Pjl7Mki=
MCF7 NV7W[VdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRjNyIN88US=> NVXidnZCOjJ|Nkm5Nlg>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of AZD4547 at 3 mg/kg twice daily in mice bearing KMS11 tumors results in significant tumor growth inhibition of 53% when compared with vehicle-treated controls, and AZD4547 at 12.5 mg/kg once daily or 6.25 mg/kg twice daily leads to complete tumor stasis, which is associated with dose proportional pharmacodynamic modulation of phospho-FGFR3 and reduced KMS11 tumor cell proliferation. Moreover, oral administration of AZD4547 at 12.5 mg/kg once daily results in 65% tumor growth inhibition in the FGFR1-fusion KG1a xenograft model. At efficacious dose levels, AZD4547 does not exhibit antiangiogenic effects. AZD4547 has no significant effect on blood pressure and therefore lacks in vivo anti-KDR activity. Consistently, dosing of 6.25 mg/kg orally twice daily AZD4547 is inactive in the cediranib-sensitive xenograft models including Calu-6, HCT-15 and LoVo. [1]

Protocol

Kinase Assay:[1]
+ Expand

AZD4547 kinase activity:

The ability of AZD4547 to inhibit the human recombinant kinase activities of FGFR1-3 is tested using ATP concentrations at, or just below, the respective Km.
Cell Research:[1]
+ Expand
  • Cell lines: KG1a, Sum52-PE, KMS11, and MCF7
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of AZD4547 for 72 hours. The antiproliferative IC50 values are obtained by MTS proliferation assay. For fluorescence-activated cell sorting (FACS), cells are fixed with 70% ethanol and then incubated with propidium iodide/RNase A labeling solution. Cell cycle profiles are assessed with a FACSCalibur instrument and CellQuest analysis software. For apoptotic analysis, cells and media are gently harvested and centrifuged, followed by washing of cell pellets. Cells are then processed for Annexin V-fluorescein isothiocyanate (FITC) staining and propidium iodide uptake. The proportion of cells staining positive for Annexin V are then assessed with a FACSCalibur instrument and quadrant sorting is done by CellQuest analysis software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female swiss derived nude (nu/nu) and severe combined immunodeficient mice (SCID) injected s.c. with LoVo, HCT-15, Calu-6, KMS11 or KG1a
  • Formulation: Formulated in a 1% (v/v) solution of polyoxyethylenesorbitan monooleate (Tween-80) in deionized water
  • Dosages: 1.5-50 mg/kg
  • Administration: Oral gavage once daily or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (198.45 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 463.57
Formula

C26H33N5O3

CAS No. 1035270-39-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02546661 Recruiting Muscle Invasive Bladder Cancer AstraZeneca October 2016 Phase 1
NCT02824133 Recruiting Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT02664935 Recruiting Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centre Network March 2015 Phase 2
NCT02965378 Active, not recruiting Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) June 2014 Phase 2|Phase 3
NCT02154490 Recruiting Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma Southwest Oncology Group|National Cancer Institute (NCI) June 2014 Phase 2|Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy AZD4547 | AZD4547 supplier | purchase AZD4547 | AZD4547 cost | AZD4547 manufacturer | order AZD4547 | AZD4547 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID